Novavax (NVAX) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results
March 18, 2019 4:05 PM EDTGAITHERSBURG, Md., March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018.
In 2018, we committed to focus on our two lead programs, ResVax and Nanoflu, and reflecting on last years activities, I am proud to say we have achieved significant results for both, said Stanley C. Erck, President and CEO of Novavax, Inc. Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to... More
